For the approximately 500,000 Americans living with Crohn's disease, the standard treatment toolkit has long consisted of immunosuppressants, biologics, and steroids -- drugs that manage symptoms by suppressing the immune system, often at considerable cost and with significant side effects. A new wave of clinical trial data, published this spring, suggests that something far simpler may work: food.

The most striking result came from Stanford University, where gastroenterologist Sidhartha Sinha led a trial of a fasting-mimicking diet in patients with mild to moderate Crohn's disease. The results, published in Nature Medicine, showed that patients who followed a structured five-day fasting-mimicking protocol each month for three months experienced a 40 percent reduction in disease activity compared to those who continued their usual diet. [1] More than 70 percent of participants in the diet group achieved clinical response. The reductions were not marginal. They were comparable to what some biologic drugs achieve in early trials.

The fasting-mimicking diet is not a fast. Developed by Valter Longo at the University of Southern California, it is a carefully calibrated low-calorie, plant-based meal plan designed to trigger the cellular changes associated with fasting -- autophagy, reduced inflammation, immune system recalibration -- while still providing enough nutrition to be sustainable over multiple cycles. [2] The Stanford trial was the first to test it rigorously in Crohn's patients, and the results caught the gastroenterology community's attention.

ScienceDaily reported on April 3 that a separate clinical trial, launched at multiple sites, is now testing dietary interventions as primary treatment for inflammatory bowel disease rather than as adjuncts to medication. [3] The trial's design reflects a shift in how researchers are thinking about diet and IBD: not as a lifestyle recommendation but as a therapeutic intervention with measurable clinical endpoints.

Meanwhile, a team at the University of Calgary published results from a trial of intermittent fasting in Crohn's patients, using an eight-hour eating window. The Calgary data, reported by EurekAlert, showed that patients who adhered to the restricted eating window for twelve weeks had fewer flare-ups and lower inflammatory markers than the control group. [4] The effect size was modest but consistent, and the trial's principal investigator noted that the intervention cost nothing and required no prescription.

The convergence matters. Two independent research groups, using different dietary strategies, found that structured eating patterns reduced Crohn's disease activity in controlled trials. Neither trial was large -- the Stanford study enrolled 73 patients, the Calgary trial 58 -- and both were open-label, meaning participants knew which group they were in. These are real limitations. But the direction of evidence is consistent, and it arrives at a moment when the cost of biologic therapy for Crohn's can exceed $30,000 per year.

US News reported that the findings have reignited debate within gastroenterology about whether diet should be considered a first-line therapy for mild Crohn's, rather than an afterthought discussed at the end of a clinic visit. [5] The American Gastroenterological Association has historically been cautious about dietary recommendations, citing insufficient evidence. That caution is becoming harder to maintain.

The patients in these trials were not replacing their medications. They were adding a dietary protocol. But the implication is clear: for a subset of Crohn's patients, what they eat and when they eat it may matter as much as what they take. The Stanford data showed that the fasting-mimicking diet reduced C-reactive protein, a standard marker of systemic inflammation, by nearly half. That is a drug-level effect from a meal plan.

None of this constitutes proof. The trials are small, the follow-up is short, and the placebo effect in dietary studies is notoriously large. But for patients who have cycled through biologics, dealt with side effects, and been told that diet "might help but we don't really know," these trials offer something that has been in short supply: evidence.

-- Nora Whitfield, Chicago